{"id":"NCT01341912","sponsor":"Octapharma","briefTitle":"Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)","officialTitle":"Clinical Study to Investigate the Long-Term Efficacy, Safety and Immunogenicity of Human-cl rhFVIII in Previously Treated Patients With Severe Haemophilia A - Extension Study to GENA-01","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2012-08","completion":"2012-08","firstPosted":"2011-04-26","resultsPosted":"2014-02-03","lastUpdate":"2020-03-17"},"enrollment":3,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Severe Hemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"Human-cl rhFVIII","otherNames":[]}],"arms":[{"label":"Human-cl rhFVIII","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to study the long-term efficacy, safety and tolerability of Human-cl rhFVIII in previously treated patients with severe hemophilia A.","primaryOutcome":{"measure":"Long-term Immunogenicity","timeFrame":"up to 3 years","effectByArm":[{"arm":"Human-cl rhFVIII","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":2,"countries":["United States","Bulgaria"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":3},"commonTop":[]}}